Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 12/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21122126 | 0.89 | PDK2 (0.46) | LSSPDK2KAT6AKAT5MAPT | |
| SCHEMBL21114043 | 0.86 | LSS (0.38) | LSSPDK2IDO1 | |
| SCHEMBL21114096 | 0.83 | LSS (0.42) | LSSPDK2KMT2AMEN1ALDH1A1 | |
| SCHEMBL21113957 | 0.82 | PDK2 (0.42) | LSSPDK2KMT2AMEN1KAT6A | |
| SCHEMBL21114074 | 0.81 | LSS (0.47) | LSSPDK2KMT2AMEN1ALDH1A1 | |
| SCHEMBL21114154 | 0.81 | LSS (0.47) | LSSPDK2KMT2AMEN1ALDH1A1 | |
| SCHEMBL21114024 | 0.81 | LSS (0.41) | LSSKMT2AMEN1IDO1ALDH1A1 | |
| SCHEMBL21114175 | 0.80 | LSS (0.46) | LSSPDK2KMT2AMEN1KAT6A | |
| SCHEMBL21113961 | 0.78 | LSS (0.41) | LSSPDK2KMT2AMEN1IDO1 | |
| SCHEMBL21114116 | 0.78 | LSS (0.55) | LSSKMT2AMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, SERPINB1 | LSS 438/4885PDK2 3088/4885KMT2A 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.